Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Voglibose. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGAM known ✓ | O43451 | 18/20 | 1.00 |
| ▸ | GAA known ✓ | P10253 | 2/20 | 1.00 |
| ▸ | SI known ✓ | P14410 | 17/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Voglibose SCHEMBL2906102 | 1.00 | MGAM (1.00) | MGAMGAALMNASI | |
| Voglibose SCHEMBL27565869 | 1.00 | MGAM (1.00) | MGAMGAALMNASI | |
| Voglibose SCHEMBL17396338 | 1.00 | MGAM (1.00) | MGAMGAALMNASI | |
| Voglibose SCHEMBL14992258 | 1.00 | MGAM (1.00) | MGAMGAALMNASI | |
| Voglibose SCHEMBL6245153 | 0.98 | MGAM (0.97) | MGAMGAALMNASI | |
| Voglibose SCHEMBL5028621 | 0.98 | MGAM (0.97) | MGAMGAALMNASI | |
| Voglibose SCHEMBL11286105 | 0.98 | MGAM (0.97) | MGAMGAALMNASI | |
| Voglibose SCHEMBL3244186 | 0.98 | MGAM (0.97) | MGAMGAALMNASI | |
| Voglibose SCHEMBL10670275 | 0.98 | MGAM (0.97) | MGAMGAALMNASI | |
| Voglibose SCHEMBL1116195 | 0.98 | MGAM (0.97) | MGAMGAALMNASI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 88029 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260124282-A1 | DECORIN FOR ITS USE IN THE TREATMENT OF DIABETES | CENTRE EUROPEEN D'ETUDE DU DIABETE (FR) | 2026-05-07 | — | — | US | claimed |
| WO-2026087680-A1 | TREATMENT FOR CARDIOVASCULAR DISEASE | SAPREME TECHNOLOGIES B.V. (NL) | 2026-04-30 | — | — | WO | claimed |
| US-20260085061-A1 | PHTHALAZINE DERIVATIVES AS PYRUVATE KINASE MODULATORS | SITRYX THERAPEUTICS LIMITED (GB) | 2026-03-26 | — | — | US | claimed |
| EP-4705280-A1 | DIARYL UREA-BASED COMPOUNDS AND RELATED COMPOSITIONS AND METHODS OF USE IN THE TREATMENT OF DIABETES MELLITUS AND NEURODEGENERATIVE DISEASE | Purdue Research Foundation (US) | 2026-03-11 | — | — | EP | claimed |
| EP-3608338-B1 | HUMAN ANTIBODIES TO THE GLUCAGON RECEPTOR | REGENERON PHARMA (US) | 2026-03-11 | — | — | EP | claimed |
| EP-4684799-A2 | ANTIBODIES THAT DISRUPT THE INTERACTION OF GAL3 AND INSULIN RECEPTOR OR INTEGRINS AND METHODS OF USE THEREOF | TrueBinding, Inc. (US) | 2026-01-28 | — | — | EP | claimed |
| US-12508301-B2 | Decorin for its use in the treatment of diabetes | CENTRE EUROPEEN D'ETUDE DU DIABETE (FR) | 2025-12-30 | — | — | US | claimed |
| US-20250360215-A1 | PHARMACEUTICAL COMBINATIONS AND METHODS FOR PREVENTING OR TREATING NEURODEGENERATIVE DISEASES | YUH CHIOU HWA (US) | 2025-11-27 | — | — | US | claimed |
| US-20250325536-A1 | THERAPEUTIC USES OF GLP1R AGONISTS | VTV THERAPEUTICS LLC (US) | 2025-10-23 | — | — | US | claimed |
| EP-4633638-A1 | TREATMENT OF PSYCHOLOGICAL FACTORS AFFECTING OTHER MEDICAL CONDITIONS (PFAOMC) | Luminous Mind Inc. (US) | 2025-10-22 | — | — | EP | claimed |
| EP-0001270-A1 | Analogues of prostacycline, methods for their preparation and their use in the treatment of circulatory diseases | HOECHST AKTIENGESELLSCHAFT (DE) | 1979-04-04 | — | — | EP | claimed |
| EP-0001066-A1 | Stable suspensions of inorganic fillers in organic polyols and their application to the preparation of cellular and non-cellular polyurethanes | BAYER AG (DE) | 1979-03-21 | — | — | EP | claimed |
| EP-0000694-A1 | Process for the preparation of quaternary phosphonium hydroxides | HOECHST AKTIENGESELLSCHAFT (DE) | 1979-02-21 | — | — | EP | claimed |
| EP-0000741-A2 | Indolacetoxyacetylaminoacid derivatives, process for their preparation and their use in drugs | Troponwerke GmbH & Co. KG (DE) | 1979-02-21 | — | — | EP | claimed |
| EP-0000478-A1 | Process for the preparation of acyloins | Henkel Kommanditgesellschaft auf Aktien (DE) | 1979-02-07 | — | — | EP | claimed |
| EP-0000538-A1 | 6,7-Dihydro-5H,13H-quinazolino(3,2-a)(1,4)benzodiazepine-5,13-diones, process for their preparation and their use as medicaments. | BAYER AG (DE) | 1979-02-07 | — | — | EP | claimed |
| EP-0000518-A1 | Process for the chemical resolution of racemic mandelic acid | RIEDEL-DE HAEN AKTIENGESELLSCHAFT (DE) | 1979-02-07 | — | — | EP | claimed |
| EP-0000574-A1 | Benzimidazole-2 derivatives, their preparation and their use for the preparation of medicaments | CIBA-GEIGY AG (CH) | 1979-02-07 | — | — | EP | claimed |
| EP-0000373-A1 | Imidazole carboxylic acids and derivatives thereof, process for their preparation and their use as plant growth regulants or plant protection agents | HOECHST AKTIENGESELLSCHAFT (DE) | 1979-01-24 | — | — | EP | claimed |
| EP-0000203-A1 | 1-Ethyl-7-chloro-6-fluoro-4-quinolone-3-carboxylic acid, its preparation and application as plant bactericide | CIBA-GEIGY AG (CH) | 1979-01-10 | — | — | EP | claimed |